Table 2A.
Characteristics in Phase 2 Trials
| Author | Condition | Age/Sex (n) | Group (n) | Intervention | Duration |
|---|---|---|---|---|---|
| Bouras2 | Functional constipation | 41 ± 3/M (4):F (36) | P 2 mg (13)/P 4 mg (11)/Placebo (14) | P 2, 4 mg/day | 1 week |
| Krogh88 | Chronic constipation after spinal cord injury | ≥18 years/M (16):F (6) | P 1 mg (8)/P 2 mg (7)/Placebo (7) | P 1, 2 mg/day | 4 weeks |
| Emmanuel89 | Chronic idiopathic constipation | ≥18 years/F (74) | P (37)/Placebo (36) | P 1 mg/day | 4 weeks |
| Sloots90 | Chronic functional constipation | 18–70 years/M (3):F (25) | P 1 mg (12)/P 2 mg (16) | P 1, 2 mg/day | 2 weeks |
| Camilleri22 | Elderly patients with constipation residing in a nursing facility | Elderly patients (range: 65–98 years)/M (24):F (65) | P 0.5 mg (21)/P 1 mg (24)/P 2 mg (26)/Placebo (18) | P 0.5, 1, 2 mg/day | 4 weeks |
| Coremans91 | Chronic constipation | 18–75 years/M (1):F (52) | P (27)/Placebo (26) | P 4 mg/day | 4 weeks |
| Sloots70 | Opioid-induced constipation | ≥18 years/NA | P 2 mg (66)/P 4 mg (64)/Placebo (66) | P 2, 4 mg/day | 4 weeks |